^
4d
New P2 trial • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)
4d
New P2 trial
|
Fruzaqla (fruquintinib) • leucovorin calcium • Tomudex (raltitrexed)
4d
New P1/2 trial • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
28d
New P2 trial • Combination therapy
|
Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
1m
A nomogram construction and multicenter validation for predicting overall survival after fruquintinib application in patients with metastatic colorectal cancer: a multicenter retrospective study. (PubMed, Therap Adv Gastroenterol)
Finally, the reliability of the model was also verified through the risk classification using the nomogram. We constructed a nomogram for mCRC treated with fruquintinib based on six variables that may be used to assist in personalizing the use of the drug.
Retrospective data • Journal • Metastases
|
CA 19-9 (Cancer antigen 19-9)
|
Fruzaqla (fruquintinib)
1m
Clinical research progress of fruquintinib in the treatment of malignant tumors. (PubMed, Invest New Drugs)
Therefore, this article conducts a systematic review encompassing the mechanism of action, pharmacokinetics, clinical efficacy, and safety profile of fruquintinib. Through this review, we aimed to offer a reference for the clinical application and subsequent development of fruquintinib.
Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
|
Fruzaqla (fruquintinib)
2ms
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (clinicaltrials.gov)
P1, N=129, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed
Trial completion • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • RAS wild-type • PTEN mutation + HR positive
|
Fruzaqla (fruquintinib)
2ms
New trial • Metastases
|
Fruzaqla (fruquintinib) • Ariely (adebrelimab)
2ms
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma (clinicaltrials.gov)
P2, N=29, Active, not recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Dec 2024
Enrollment closed • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
2ms
New P2 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
|
MSI-H/dMMR • HER-2 negative
|
5-fluorouracil • Fruzaqla (fruquintinib) • leucovorin calcium • Kaitanni (cadonilimab)
2ms
New P2 trial • IO biomarker • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Fruzaqla (fruquintinib)
2ms
Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors. (PubMed, J Gastrointest Oncol)
The real-world efficacy and safety of fruquintinib in advanced CRC patients are numerically superior to that in the previous phase III studies. SMI, brain metastasis and CEA could serve as potential markers for patient selection.
Journal • Real-world evidence • Real-world • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
Fruzaqla (fruquintinib)
2ms
New P3 trial • Metastases
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
2ms
Fruquintinib-Induced Cerebellar Hemorrhage in Left-Sided Descending Metastatic Colorectal Adenocarcinoma: A Case Report and Risk Assessment. (PubMed, Cureus)
However, its use is associated with significant bleeding risks, including rare but severe complications such as cerebellar hemorrhage. This case report presents a patient with mCRC who developed a cerebellar hemorrhage shortly after initiating fruquintinib therapy, highlighting the need for careful patient monitoring and individualized risk assessment to mitigate such serious adverse events.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CHEK2 (Checkpoint kinase 2)
|
Fruzaqla (fruquintinib)
3ms
New P4 trial • Metastases
|
Fruzaqla (fruquintinib)
3ms
New trial • Metastases
|
BRAF (B-raf proto-oncogene)
|
Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)
3ms
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer (clinicaltrials.gov)
P2, N=68, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P2 trial • Circulating tumor DNA • Metastases
|
BRAF (B-raf proto-oncogene)
|
Tyvyt (sintilimab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)
3ms
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. (PubMed, J Med Econ)
A budget impact model was developed to compare two scenarios: a reference scenario in which patients received regorafenib, trifluridine/tipiracil, or trifluridine/tipiracil with bevacizumab and an alternative scenario in which patients received reference scenario treatments or fruquintinib. PMPM costs from the Medicare perspective were greater than the base-case (commercial) ($0.17 vs. $0.07) due to higher incidence of CRC in that population. Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.
Journal • HEOR • Metastases
|
EGFR (Epidermal growth factor receptor)
|
Avastin (bevacizumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
4ms
Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study. (PubMed, Orthop Surg)
Fruquintinib may be a potential option for patients with refractory sarcoma after developing several lines of TKI resistance, with a satisfactory efficacy and safety profile in combination therapy. However, the degree of contribution of fruquintinib to results is unclear when combined with other effective substances. Additional prospective trials of fruquintinib should be conducted, especially involving different pathological types and combination regimens.
Retrospective data • Journal
|
FLT1 (Fms-related tyrosine kinase 1)
|
Fruzaqla (fruquintinib)
4ms
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial (ESMO 2024)
These data demonstrate that F consistently improved OS vs P in pts with previously treated mCRC with and without liver mets at baseline. F is an effective and tolerable treatment option for pts with mCRC regardless of liver mets.
P3 data • Clinical • Metastases
|
Fruzaqla (fruquintinib)
4ms
New trial
|
BRAF (B-raf proto-oncogene)
|
Fruzaqla (fruquintinib)
4ms
New P2 trial
|
KRAS (KRAS proto-oncogene GTPase) • MLH1 (MutL homolog 1)
|
Fruzaqla (fruquintinib)
4ms
New P3 trial • Combination therapy
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Epidaza (chidamide)
4ms
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Sun Yat-sen University | N=12 --> 0 | Trial completion date: Jan 2026 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2023 --> Jul 2025
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • IO biomarker • Metastases
|
ARID1A (AT-rich interaction domain 1A)
|
Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
4ms
New P1/2 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Fruzaqla (fruquintinib)
5ms
New trial • Real-world evidence • Real-world • Metastases
|
5-fluorouracil • oxaliplatin • Fruzaqla (fruquintinib)
5ms
New trial • Checkpoint inhibition • Real-world evidence • Real-world • Metastases
|
capecitabine • oxaliplatin • Fruzaqla (fruquintinib)
5ms
New P2 trial • Combination therapy • Metastases
|
Tyvyt (sintilimab) • albumin-bound paclitaxel • Fruzaqla (fruquintinib) • Teysuno (gimeracil/oteracil/tegafur)
5ms
New P2 trial
|
5-fluorouracil • Tyvyt (sintilimab) • oxaliplatin • Fruzaqla (fruquintinib) • leucovorin calcium
5ms
New P2/3 trial • Metastases
|
Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Fruzaqla (fruquintinib)
5ms
New P2/3 trial
|
5-fluorouracil • oxaliplatin • Fruzaqla (fruquintinib) • leucovorin calcium
6ms
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. (PubMed, Nat Med)
In the multicenter, double-blind phase 3 FRUTIGA trial, 703 patients with advanced gastric or gastroesophageal junction adenocarcinoma who progressed on fluorouracil- and platinum-containing chemotherapy were randomized (1:1) to receive fruquintinib (an inhibitor of vascular endothelial growth factor receptor-1/2/3; 4 mg orally, once daily) or placebo for 3 weeks, followed by 1 week off, plus paclitaxel (80 mg/m2 intravenously on days 1/8/15 per cycle). Fruquintinib plus paclitaxel as a second-line treatment significantly improved PFS, but not OS, in Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma and could potentially be another treatment option for these patients. ClinicalTrials.gov registration: NCT03223376 .
P3 data • Journal
|
FLT1 (Fms-related tyrosine kinase 1)
|
paclitaxel • 5-fluorouracil • Fruzaqla (fruquintinib)
6ms
New P2 trial
|
Fruzaqla (fruquintinib) • Teysuno (gimeracil/oteracil/tegafur) • Tomudex (raltitrexed)
6ms
New P2 trial
|
AiRuiKa (camrelizumab) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib)
6ms
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma (clinicaltrials.gov)
P=N/A, N=60, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New trial • Combination therapy • Metastases
|
albumin-bound paclitaxel • Fruzaqla (fruquintinib)
6ms
BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • zanidatamab (ZW25) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
6ms
Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2 (ESMO-GI 2024)
P3 | "In the heavily pretreated pt population of FRESCO-2, the number of metastatic sites and time from diagnosis of metastasis to randomization are important prognostic factors. In pts with more indolent or more aggressive disease, F was effective in improving OS, PFS, and delay to PS deterioration vs P."
Clinical
|
Fruzaqla (fruquintinib)
6ms
New P2 trial • Metastases
|
paclitaxel • Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)
7ms
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial. (ASCO 2024)
P3 | "In the FRESCO-2 trial, F + BSC demonstrated a clinically meaningful quality-adjusted survival benefit compared with P + BSC in heavily pretreated patients with refractory mCRC. Clinical trial information: NCT04322539."
Clinical
|
Fruzaqla (fruquintinib)
7ms
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2. (ASCO 2024)
P3 | "In FRESCO, eligible pts had received ≥2 prior chemotherapy regimens and were permitted to have received prior anti-VEGF and/or anti-EGFR therapies, whereas in FRESCO-2, in addition to standard chemotherapies, anti-VEGF, and anti-EGFR therapies if indicated, prior exposure to trifluridine/tipiracil (TAS) and/or regorafenib (rego) was required. F is effective in mCRC with a manageable safety profile regardless of prior TAS or rego tx and sequence. Improvement with F was similar for OS and PFS despite the number and sequence of prior regimens. F provides a new tx option for pts with previously treated mCRC regardless of prior TAS or rego exposure."
Clinical
|
Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
7ms
Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer. (ASCO 2024)
Background: Recent clinical trials support regorafenib dose optimization (ReDO), a combination therapy with trifluridine/tipiracil and bevacizumab (TAS-BEV), and fruquintinib (FRUQ) for the treatment of refractory metastatic colorectal cancer (mCRC). ReDO was cost-effective compared with TAS-BEV and FRUQ, regardless of previous use of anti-VEGF therapy. In the base case, ReDO had a lower treatment cost than TAS-BEV and FRUQ, especially during the first month of dose optimization. TAS-BEV had the highest total cost, partly due to the cost of managing neutropenia and GCSF use.
HEOR • Cost-effectiveness • Cost effectiveness • Metastases
|
Avastin (bevacizumab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
7ms
HCCSC-C03: Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (clinicaltrials.gov)
P4, N=51, Active, not recruiting, Zhongnan Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 mutation • HER-2 expression
|
Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)